November 1, 2017 / 12:11 PM / a month ago

BRIEF-Neos Therapeutics receives paragraph IV certification from Teva Pharmaceuticals USA

Nov 1 (Reuters) - Neos Therapeutics Inc:

* Neos Therapeutics-co received paragraph iv certification from teva pharmaceuticals usa that teva submitted anda for generic version of cotempla xr-odt​

* Neos - notice alleges that 3 U.S. Patents in FDA’s orange book for cotempla XR-ODT will not be infringed by Teva’s generic version of cotempla XR-ODT

* Neos - is evaluating paragraph IV certification from Teva Pharmaceuticals USA, intends to "vigorously enforce" ip rights relating to cotempla XR-ODT​ Source text: (bit.ly/2z2QTYT) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below